HB 195 amends the Texas Controlled Substances Act to add mifepristone and misoprostol to Schedule IV, alongside carisoprodol. Schedule IV is the category of controlled substances under state law that generally covers drugs with accepted medical uses but some potential for abuse or dependence. The bill is a targeted classification measure rather than a broader criminal justice or health care overhaul.
The bill also includes a standard applicability clause providing that the new classification applies only to offenses committed on or after the effective date, preserving prior law for earlier conduct. It takes effect January 1, 2026. In practical terms, the bill would change how these two medications are regulated, possessed, dispensed, and prosecuted under Texas controlled substances law, affecting patients, prescribers, pharmacists, and law enforcement.
Impact
By amending Section 481.037 of the Health and Safety Code, the bill expands the list of Schedule IV controlled substances to include mifepristone and misoprostol. This would place those medications under the regulatory framework of the Texas Controlled Substances Act, potentially affecting prescribing, dispensing, storage, recordkeeping, and criminal penalties tied to controlled-substance offenses. The bill applies prospectively only, so conduct occurring before January 1, 2026 would remain governed by prior law.
Sentiment
No committee transcripts or recorded votes were provided, so there is no direct evidence of legislative debate or vote sentiment in the supplied materials. Based on the text alone, the bill appears to be a straightforward regulatory change with significant policy implications, especially because it concerns medications commonly associated with reproductive health care. The absence of recorded discussion makes it difficult to assess whether support or opposition was broad, but the subject matter suggests it could draw strong views from both public health and reproductive rights perspectives.
Contention
The main point of contention is likely the inclusion of mifepristone and misoprostol in Schedule IV, because those drugs are widely used in reproductive and abortion-related care as well as other medical contexts. Supporters may view the bill as a controlled-substances enforcement measure, while opponents may argue it would restrict access to legitimate medical treatment, create barriers for patients and providers, or signal an effort to regulate abortion-related medications through drug-control law. No specific committee arguments are available in the provided record, so these are the likely areas of dispute rather than documented positions.
Relating to the use, possession, delivery, or manufacture of testing equipment that identifies the presence of a substance listed in Penalty Group 1-B or xylazine.
Relating to the protection and detention of a juvenile who engages in delinquent conduct or commits a felony offense while committed to the custody of the Texas Juvenile Justice Department; changing the eligibility for community supervision; redefining habitual felony conduct.
Relating to procedures related to juvenile justice proceedings, the adjudication and disposition of cases involving delinquent conduct, and certain offenses or conduct committed by a child or by a person placed in or committed to certain juvenile facilities; changing the eligibility for community supervision.